December 7, 2023 – In August 2023, the pCPA engaged with clinicians, patient groups and industry to present and hear feedback on a set of principles and conditions for a pCPA Temporary Access Process (pTAP).
pan-Canadian Pharmaceutical Alliance
Conducting collective expert-informed negotiations for drugs.
What's New at the pCPA
October 26, 2023 – The pCPA Board of Directors is thrilled to release the organization’s inaugural report, a report that is a testament to the transformative nature of this past year.
The pan-Canadian Pharmaceutical Alliance (pCPA) is an independent organization whose membership includes the provincial, territorial and federal governments. Member jurisdictions collaborate on a range of public drug plan initiatives to increase and manage access to clinically effective and affordable drug treatments.
One of the pCPA’s key roles is to conduct joint negotiations for brand name and generic drugs in Canada in order to achieve greater value for publicly funded drug programs and patients through its combined negotiating power. Its objectives are to:
- Increase access to clinically relevant and cost-effective treatments
- Achieve consistent and lower drug costs
- Improve consistency in funding decisions
- Reduce duplication and optimize resource utilization
Member Jurisdictions
The pCPA member jurisdictions include public drug plans from:
